Business Context and Reporting Period
This Form 8-K is a current report filed by Signal Genetics, Inc. (not Viridian Therapeutics, Inc.) on March 16, 2016. The filing serves to disclose a business update and financial results for the fourth quarter and full year ended December 31, 2015, via a press release incorporated by reference as Exhibit 99.1.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
The filing indicates the Company is reporting fourth quarter and full-year 2015 financial results and highlighting recent achievements. Specific details regarding material changes compared to prior periods are not present in the Form 8-K text provided.
Guidance, Outlook, and Management Commentary
- Management Commentary: The Company issued a press release titled "Signal Genetics Highlights Recent Achievements and Reports Fourth Quarter and Full-Year 2015 Financial Results."
- Conference Call: Management held a live conference call and webcast on March 16, 2016, at 4:30 p.m. ET to discuss the results. A recording was available until March 30, 2016.
- Forward-Looking Statements: The filing includes standard disclaimers that the information is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 Press Release, as they are not listed in the Form 8-K body.
- Confirm the details of "recent achievements" mentioned in the press release title to understand operational progress.
- Review the conference call transcript or recording for management's specific commentary on the 2015 results and future outlook.
- Note that the registrant is Signal Genetics, Inc., ensuring any analysis is attributed to the correct entity.